The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …

With the recent developments of adoptive T cell therapies and the use of new monoclonal
antibodies against the immune checkpoints, immunotherapy is at a turning point. Key …

Recent advances in immune checkpoint blockade therapy have revolutionized the treatment
of cancer. Tumor-specific antigens that are generated by somatic mutation, neoantigens, can …

Cancer immunotherapy has experienced remarkable advances in recent years. Striking
clinical responses have been achieved for several types of solid cancers (eg melanoma …

Immune-checkpoint inhibition provides an unmatched level of durable clinical efficacy in
various malignancies. Such therapies promote the activation of antigen-specific T cells …

The recent clinical successes of immune checkpoint blockade and chimeric antigen receptor
T cell therapies represent a turning point in cancer immunotherapy. These successes also …

Cancer elimination in humans can be achieved with immunotherapy that relies on T
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …

Immune checkpoint blockade, which blocks inhibitory signals of T cell activation, has shown
tremendous success in treating cancer, although success still remains limited to a fraction of …

Cancer immunotherapy has dramatically changed the approach to cancer treatment. The
aim of targeting the immune system to recognize and destroy cancer cells has afforded …

Highlights•Cancer vaccines have not generated effective anti-tumor responses due to
suboptimal immunogenicity.•Peptide vaccines with appropriate adjuvants are the most …